Ctrl K
PMN trades 94.8% below Wall Street's consensus target of $26.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PMN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 2, 2026, ProMIS Neurosciences, Inc. (PMN) has a Wall Street consensus price target of $26.00, based on estimates from 3 covering analysts. With the stock currently trading at $13.35, this represents a potential upside of +94.8%. The company has a market capitalization of $17M.
Analyst price targets range from a low of $19.00 to a high of $33.00, representing a 54% spread in expectations. The median target of $26.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PMN trades at a trailing P/E of -0.6x. Analysts expect EPS to grow -14.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRTAProthena Corporation plc | $503M | $9.61 | $24.50 | +154.9% | Buy | 87.4x | 28 |
 ARVNArvinas, Inc. | $599M | $9.28 | $13.57 | +46.2% | Buy | — | 26 |
 ACADACADIA Pharmaceuticals Inc. | $4.9B | $28.89 | $33.35 | +15.4% | Buy | 47.1x | 37 |
 SAVACassava Sciences, Inc. | $45M | $0.94 | — | — | Buy | — | 12 |
 NRXPNRx Pharmaceuticals, Inc. | $59M | $3.44 | — | — | — | — | — |
 BIIBBiogen Inc. | $31.9B | $216.04 | $243.60 | +12.8% | Buy | 17.3x | 49 |
 LLYEli Lilly and Company | $1.1T | $1159.93 | $1341.63 | +15.7% | Buy | 31.9x | 45 |
 ESPREsperion Therapeutics, Inc. | $661M | $3.18 | $3.19 | +0.3% | Hold | — | 25 |
 IONSIonis Pharmaceuticals, Inc. | $10.0B | $59.88 | $93.36 | +55.9% | Buy | — | 33 |
 ALNYAlnylam Pharmaceuticals, Inc. | $32.9B | $246.11 | $344.83 | +40.1% | Buy | 37.8x | 52 |
Quick answers to the most common questions about buying PMN stock.
The consensus Wall Street price target for PMN is $26, representing 94.8% upside from the current price of $13.35. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PMN has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $26 implies 94.8% upside from current levels.
PMN's current price is $13.35 with a consensus target of $26 (94.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $33 for PMN, while the most conservative target is $19. The consensus of $26 represents the median expectation. These targets typically reflect 12-month expectations.
PMN is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PMN stock forecast based on 3 Wall Street analysts shows a consensus price target of $26, with estimates ranging from $19 (bear case) to $33 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PMN, with a "Buy" consensus rating and $26 price target (94.8% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PMN analyst price targets range from $19 to $33, a 54% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $26 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.